GlassScriptPhysician profile
Keerthana Kumar
NPI 1932737079
$8,025.93
in general payments reported to CMS, 2019-2025
10 companies · $3,867 in 2025
The $3,867 reported for 2025 was more than what 91% of Public Health & General Preventive Medicine providers received nationally (typical 2025 total: $95.27).
See the full distribution for Public Health & General Preventive Medicine
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,653 · 2024: $2,506 · 2025: $3,867.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,470 · Consulting Fee: $1,525 · Travel and Lodging: $1,026 · Education: $4.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,470.32 |
| Consulting Fee | $1,525.00 |
| Travel and Lodging | $1,025.89 |
| Education | $4.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $2,664.23 | 2023-2025 | |
| Abbvie INC. | $1,998.77 | 2024-2025 | |
| Ipsen Innovation | $1,320.89 | 2023 | Dysport |
| Teva Pharmaceuticals USA, INC. | $981.27 | 2023-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Lundbeck LLC | $628.93 | 2024-2025 | Vyepti |
| E.R. Squibb & Sons, L.L.C. | $149.71 | 2024 | Cobenfy |
| Alnylam Pharmaceuticals INC. | $123.00 | 2024 | Amvuttra |
| Ucb, INC. | $104.62 | 2024 | |
| Tonix Medicines, INC. | $30.90 | 2025 | Zembrace Symtouch |
| Irhythm Technologies, INC. | $23.61 | 2023 | Zio Xt Patch |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keerthana Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.